Overview

DNS-7801 vs. Placebo in Parkinson's Disease

Status:
Terminated
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, two-part placebo-controlled parallel group outpatient treatment study that will utilize standard Parkinson's Disease measures to evaluate the effect of DNS-7801
Phase:
Phase 2
Details
Lead Sponsor:
Dart NeuroScience, LLC